The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Company (EMA) has given a sure belief for Blenrep (belantamab mafodotin) for the treatment of relapsed or refractory a pair of myeloma. The drug is an antibody drug conjugate comprising a humanized IgG1κ monoclonal antibody focusing on the B-cell maturation antigen (BCMA…
Read Extra
